Form 4: Amicus Therapeutics Acquired by BioMarin for $14.50/Share

Amicus Therapeutics Chief Legal Officer Ellen Rosenberg reports the disposal of all equity holdings following the company's acquisition by BioMarin Pharmaceutical Inc.

Summary

• Ellen Rosenberg, Chief Legal Officer of Amicus Therapeutics, disposed of all direct and indirect common stock holdings.
• The disposal occurred on April 27, 2026, in connection with the acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc.
• A total of 463,898 shares held directly and 15,000 shares held by a spouse were disposed of at a price of $14.50 per share.
• Multiple tranches of stock options with exercise prices ranging from $9.41 to $14.24 were cancelled and converted into cash payments based on the $14.50 acquisition price.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing documenting the final equity liquidation of an executive following a completed corporate acquisition.

Positives

• The acquisition by BioMarin provides liquidity to shareholders and executives at a fixed price of $14.50 per share.
• All outstanding stock options held by the reporting person were fully vested or accelerated to vest upon the merger, ensuring full value realization.

Negatives

• The reporting person no longer holds any equity interest in Amicus Therapeutics following the completion of the merger.

Risks

• As the company has been acquired, the primary risk is the integration process and the potential for future operational changes under the new parent company, BioMarin.

Future Outlook

The company has been acquired by BioMarin Pharmaceutical Inc.; therefore, no further independent forward-looking guidance for Amicus Therapeutics is provided.

Management Comments

• The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc.

Industry Context

StockSavvy.ai notes that this filing confirms the finalization of a significant M&A event in the biotechnology sector, reflecting ongoing consolidation trends where larger pharmaceutical entities acquire specialized firms to bolster their rare disease or specialty drug pipelines.

Comparison to Industry Standards

• The acquisition price of $14.50 per share represents the final exit valuation for Amicus Therapeutics shareholders.
• The treatment of unvested options via accelerated vesting is standard practice in high-value pharmaceutical M&A transactions.

Related Party Transactions

• Disposal of 15,000 shares held by the spouse of the reporting person.

Stakeholder Impact

• Shareholders have received the merger consideration of $14.50 per share.
• Employees and executives are subject to the transition and integration policies of the acquiring entity, BioMarin.

Next Steps

• Finalization of integration into BioMarin Pharmaceutical Inc.

Key Dates

Keywords

Amicus Therapeutics, BioMarin Pharmaceutical, Merger, Acquisition, Form 4, Insider Transaction, FOLD